Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Longitudinal Analysis 2010-2012

The study measures changes in company performance with regard to access to medicines and technologies for 33 relevant diseases in 103 low- and middle-income countries.

Date

01 October 2012

Download this publication

Despite many efforts and real progress in many countries, about one third of the world’s population remains without regular access to essential medicines. Most of the “bottom billion” living on less than a dollar per day are found in sub-Saharan Africa, India and other emerging economies.I Such people face many barriers to obtaining necessary medications. Lack of access may simply be due to high prices and lack of funds, but physical access to health facilities, poor quality of the product, deficient distribution systems, social and cultural barriers and irrational prescribing also play a role. In some cases, the necessary essential medicines do not exist, such as heat-stable insulin for patients without refrigerators in tropical climates, or paediatric combination syrups for treatment of HIV in young children. The responsibility for resolving these problems lies with many actors, one of which is the pharmaceutical industry.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved